Amneal Pharmaceuticals (STU:2DT) Beginning Cash Position: €177 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2DT Amneal Pharmaceuticals Inc STU:2DT
63 GF Score
Price €15.50
GF Value €6.99
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Amneal Pharmaceuticals Beginning Cash Position?

Amneal Pharmaceuticals STU:2DT -2.52% 63 Beginning Cash Position is €177 Mil as of Jun. 2026. GuruFocus rates STU:2DT with a GF Score™ of 63/100 and a GF Value™ of €6.99 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Amneal Pharmaceuticals's Beginning Cash Position for the quarter that ended in Jun. 2026 was €177 Mil.

Amneal Pharmaceuticals's quarterly Beginning Cash Position increased from Dec. 2025 (€204 Mil) to Mar. 2026 (€271 Mil) but then declined from Mar. 2026 (€271 Mil) to Jun. 2026 (€177 Mil).

Amneal Pharmaceuticals's annual Beginning Cash Position increased from Dec. 2023 (€32 Mil) to Dec. 2024 (€95 Mil) and increased from Dec. 2024 (€95 Mil) to Dec. 2025 (€101 Mil).

Amneal Pharmaceuticals Beginning Cash Position Related Terms

Amneal Pharmaceuticals Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Amneal Pharmaceuticals's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amneal Pharmaceuticals Beginning Cash Position Chart

Amneal Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 307.20 242.36 32.30 94.65 101.13

Amneal Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.30 71.29 203.60 270.69 177.43
STU:2DT
63GF Score
Amneal Pharmaceuticals Inc STU:2DT
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amneal Pharmaceuticals Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €177 Mil mean?
Amneal Pharmaceuticals (STU:2DT) has a Beginning Cash Position of €177 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Amneal Pharmaceuticals and its competitors.
Is Amneal Pharmaceuticals' Beginning Cash Position too high?
Amneal Pharmaceuticals' current Beginning Cash Position is €177 Mil. Overall, Amneal Pharmaceuticals has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amneal Pharmaceuticals' Beginning Cash Position compare to HIMS and KNSA?
Amneal Pharmaceuticals' Beginning Cash Position of €177 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Amneal Pharmaceuticals and its competitors. Amneal Pharmaceuticals's current Beginning Cash Position is €177 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amneal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amneal Pharmaceuticals (STU:2DT) is currently considered Significantly Overvalued. The stock's GF Value™ is €6.99, compared to a current price of €15.50 — trading 121.7% above its estimated fair value. The current Beginning Cash Position is €177 Mil. Amneal Pharmaceuticals' overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Amneal Pharmaceuticals (STU:2DT), the current Beginning Cash Position is €177 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amneal Pharmaceuticals (STU:2DT) Overvalued in 2026?

Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued. The current stock price of €15.50 is trading 121.7% above its estimated GF Value™ of €6.99. GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:2DT:

  • Beginning Cash Position: €177 Mil
  • GF Value™: €6.99 vs. price of €15.50 (121.7% above fair value)
  • GF Score™: 63/100 with 7 warning signs

No single metric tells the full story. See the STU:2DT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amneal Pharmaceuticals Business Description

Other Exchanges AMRX:USA
Address 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
63GF Score

Get the complete analysis for STU:2DT

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.50
Price
€6.99
GF Value